SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

SAB-142 Phase 1 trial positive topline data announced at KOL eventMIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: ...

One of the feats of adaptive immunity is its ability to recognize foreign pathogens while sparing the self. During maturation in the thymus, T cells are selected through the binding properties of ...